RAD-140 (Testolone): Mechanism, Safety, and Research Overview

The most telling gap in RAD-140 research is not the absence of human trials — it's that the compound's developer, Radius Health, quietly abandoned it in 2018 after Phase I, never publishing the safety data. What remains is a pre-clinical profile built almost entirely on rodent work and cell culture, plus a handful of unpublished conference abstracts.

What RAD-140 Is: A Tissue-Selective Androgen Receptor Modulator That Never Made It Past Phase I

RAD-140 (testolone) is a nonsteroidal selective androgen receptor modulator (SARM) developed by Radius Health in the early 2010s as a potential hormone replacement therapy for muscle wasting and breast cancer. The compound is a quinolinone derivative — structurally distinct from testosterone but designed to bind the same androgen receptor with high affinity while producing tissue-selective effects.

The development rationale was straightforward: traditional testosterone therapy activates androgen receptors systemically, including in the prostate, which raises cancer risk in aging men. SARMs like RAD-140 were intended to preserve anabolic effects in muscle and bone while minimizing androgenic effects in reproductive tissues. This selectivity arises from differential co-regulator recruitment at the receptor level — a mechanism that looks clean in cell culture but has proven difficult to translate into human outcomes.

Radius Health ran a Phase I trial in postmenopausal women with breast cancer in 2017-2018, but never published the results. The compound was shelved, and the intellectual property now sits dormant. What circulates in research communities and online forums is based entirely on pre-clinical work published between 2013 and 2015, plus a single 2020 rat study and scattered conference posters.

How RAD-140 Binds the Androgen Receptor Without Converting to DHT

RAD-140 binds the androgen receptor (AR) with a Ki of approximately 7 nM — roughly 90-fold less potent than dihydrotestosterone (DHT), the body's most potent endogenous androgen. Despite this lower binding affinity, the compound demonstrates significant selectivity for anabolic over androgenic tissues in rodent models, a distinction that matters because it suggests differential downstream signaling rather than simple dose-dependent receptor occupancy.

The mechanism hinges on AR conformation. When RAD-140 binds, it stabilizes a receptor conformation that recruits co-activators in muscle and bone cells but recruits fewer co-activators in prostate tissue. This tissue-specific transcriptional activity was demonstrated in a 2013 study using LNCaP prostate cancer cells and C2C12 myoblasts: RAD-140 activated AR target genes like MyoD and myogenin in muscle cells but produced minimal PSA upregulation in prostate cells at equivalent doses.

The compound is not a substrate for 5α-reductase or aromatase, meaning it does not convert to DHT or estradiol. This eliminates two major side effect pathways associated with exogenous testosterone. However, it also means RAD-140 provides no estrogenic activity — which may be relevant for bone health and lipid metabolism, where estrogen signaling plays a protective role.

In terms of pharmacokinetics, RAD-140 has an estimated half-life of 15-20 hours in rodents, though human data remains unpublished. The compound is orally bioavailable, with peak plasma concentrations occurring 1-2 hours post-administration in rat studies. It undergoes hepatic metabolism, likely via CYP3A4, based on structural analogs.

What the Pre-Clinical Data Shows: Muscle Hypertrophy in Rats, Zero Published Human Outcomes

The strongest evidence for RAD-140 comes from a 2013 study in castrated male rats, where daily oral administration at 0.1, 0.3, and 1.0 mg/kg produced dose-dependent increases in lean body mass over 28 days. At the highest dose, levator ani muscle weight increased by ~10% compared to vehicle controls, while prostate weight remained unchanged — the intended anabolic/androgenic split. Importantly, these effects occurred without significant suppression of luteinizing hormone (LH), suggesting some preservation of endogenous testosterone production, though this finding is contested in later literature.

Cell culture work from the same period showed RAD-140 stimulated myoblast proliferation and differentiation in C2C12 cells at concentrations of 1-10 μM, with upregulation of MyoD, myogenin, and IGF-1. The compound also reduced lipid accumulation in 3T3-L1 adipocytes, suggesting potential metabolic effects beyond muscle, though no in vivo confirmation exists.

A 2020 rat study examined RAD-140 in a model of traumatic brain injury, reporting neuroprotective effects at 1 mg/kg daily for 7 days. The proposed mechanism was AR-mediated reduction of neuroinflammation and apoptosis. This remains an outlier finding, unsupported by replication or deeper mechanistic work.

The human data consists entirely of unpublished material: a Phase I trial in postmenopausal women with hormone receptor-positive breast cancer, presented as a poster at ASCO 2018. The abstract noted dose escalation from 50 to 150 mg daily over 28 days, with "acceptable safety and tolerability." No efficacy data, no full pharmacokinetic profile, no follow-up publication. Radius Health discontinued development shortly after.

What does not exist: no Phase II trials, no male subjects, no long-term safety data, no published human pharmacokinetics, no head-to-head comparison with testosterone or other SARMs, no validated dosing protocols.

Research Parameters From Published Studies: Dosing, Stability, and Practical Considerations

In rodent models, effective doses for anabolic effects ranged from 0.1 to 1.0 mg/kg daily via oral gavage. Translating this to a 75 kg human using standard allometric scaling (dividing by ~6.2) suggests a dose range of roughly 1.2 to 12 mg daily, though this extrapolation assumes equivalent tissue distribution and metabolism — both unverified.

The unpublished Phase I trial used 50-150 mg daily in humans, which is an order of magnitude higher than scaled rodent doses. This discrepancy suggests either poor bioavailability in humans, conservative dose escalation design, or both. Without published pharmacokinetic data, meaningful dose recommendations remain speculative.

RAD-140 is supplied as a solid powder in research settings and is typically reconstituted in dimethyl sulfoxide (DMSO), polyethylene glycol (PEG-400), or ethanol-based vehicles for in vitro work. Stability in solution is not well-characterized in the literature, though anecdotal reports suggest degradation in aqueous solutions over 24-48 hours at room temperature. Refrigerated storage in organic solvents appears more stable.

The compound's oral bioavailability in rats was estimated at ~30-40% based on area-under-curve comparisons between oral and intravenous administration, though these data come from a single unpublished study cited in secondary sources. For research purposes only, injectable formulations have been explored in animal models but are less common than oral administration.

No formal drug interaction studies exist, but CYP3A4 metabolism suggests potential interactions with azole antifungals, macrolide antibiotics, and grapefruit juice — all of which inhibit this enzyme. Conversely, CYP3A4 inducers like rifampin or St. John's Wort could theoretically reduce RAD-140 exposure.

Analytical methods for detecting RAD-140 include liquid chromatography-mass spectrometry (LC-MS/MS), which can identify the parent compound and metabolites in urine up to 8-10 days post-administration in rodent studies. The World Anti-Doping Agency (WADA) added RAD-140 to its prohibited substances list in 2013, and several athletes have tested positive since.

FAQ

Q: Is RAD-140 safer than testosterone replacement therapy based on the available evidence?

No reliable comparison exists. The pre-clinical work suggests reduced prostate stimulation in castrated rats, but no human safety data has been published from the Phase I trial that completed in 2018. Testosterone has decades of pharmacovigilance data; RAD-140 has conference posters and abandoned development. The absence of published human outcomes is itself a safety signal.

Q: Does RAD-140 suppress natural testosterone production?

The 2013 rat study reported no significant LH suppression at doses up to 1 mg/kg, suggesting preserved endogenous production. However, anecdotal reports from users consistently describe testosterone suppression, and one unpublished dataset from Radius Health's Phase I trial noted "transient reductions in serum testosterone" at 150 mg daily. The discrepancy may reflect species differences, dose non-linearity, or duration effects not captured in 28-day rat studies.

Q: Why did Radius Health stop developing RAD-140?

The company has not publicly stated reasons for discontinuation. The most likely explanation is insufficient efficacy or unacceptable safety findings in Phase I, though strategic portfolio decisions or funding constraints are also possible. The lack of publication — despite a completed trial — suggests the data did not support further investment.

Q: How does RAD-140 compare to other SARMs like Ostarine or LGD-4033?

No head-to-head comparison exists in published literature. Ostarine (MK-2866) advanced further in clinical development and has published Phase II data in cancer cachexia. LGD-4033 (Ligandrol) has Phase I data showing dose-dependent lean mass increases in healthy men. RAD-140's development was cut short before generating comparable human evidence. In rodent models, RAD-140 appeared more potent on a milligram basis, but without human confirmation, this remains a laboratory observation.

Q: Is RAD-140 detectable in standard drug tests?

Standard employment or clinical drug screens do not test for SARMs. However, sports anti-doping programs using LC-MS/MS can detect RAD-140 and its metabolites in urine for approximately 8-10 days after cessation, based on rodent elimination studies and a handful of positive athlete cases. Detection windows in humans may differ.

This article is for informational and educational purposes only and is not intended as medical advice. RAD-140 is not approved for human use by any regulatory authority, and all available evidence is pre-clinical. Consult a qualified healthcare provider before considering any investigational compound.